NTRA vs. RGEN: Natera vs. Repligen Stock Comparison
How do Natera (NTRA) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Natera (NTRA) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NTRA is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.
| Profile Item | NTRA | RGEN |
|---|---|---|
| Name | Natera, Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 45.05 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 1, 2015 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| Total Return (1Y) | 61.03% | 23.28% |
| Total Return (3Y, Annualized) | 92.02% | 6.20% |
| Total Return (5Y, Annualized) | 23.20% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 52.30% | 46.73% |
| Beta (5Y) | 1.58 | 1.11 |
| Max Drawdown (5Y) | -75.72% | -64.67% |
| Avg. Volume (3M) | 1.68M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 1.09 | 0.41 |
| Sortino Ratio (1Y) | 1.63 | 0.60 |
Profitability
ROE (TTM)
Both Natera (NTRA) at -10.55% and Repligen (RGEN) at -0.57% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Natera (NTRA) at -5.66% and Repligen (RGEN) at -1.47% report negative net margin values, usually indicating net losses over the period.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Repligen (RGEN) reports 6.19%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| ROE (TTM) | -10.55% | -0.57% |
| ROA (TTM) | -6.79% | 1.40% |
| Net Margin (TTM) | -5.66% | -1.47% |
| Operating Margin (TTM) | -7.64% | 6.19% |
| Gross Margin (TTM) | 65.14% | 53.77% |
Growth
Revenue Growth
Both Natera (NTRA) at 35.90% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Neither Natera (NTRA) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 35.90% | 16.36% |
| Revenue Growth (3Y CAGR) | 41.14% | -2.70% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Both Natera (NTRA) at 2.81 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Natera (NTRA) at 0.13 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.81 | 9.88 |
| Debt / Equity (MRQ) | 0.13 | 0.33 |
| Net Debt / EBITDA | -- | -1.19 |
Dividends
Dividend Yield (TTM)
Neither Natera (NTRA) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Natera (NTRA) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Natera (NTRA) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both Natera (NTRA) at 15.49 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Repligen (RGEN) at 4.70 sits near its industry’s typical P/B ratio, while Natera (NTRA) at 23.99 prices above its benchmark range — NTRA looks rich relative to book.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | NTRA | RGEN |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 15.49 | 13.77 |
| P/B Ratio (MRQ) | 23.99 | 4.70 |
| Free Cash Flow Yield (TTM) | 0.19% | 1.01% |